Evidence map›Paper›PMID 30041763›Full record

ArticleThe Kaohsiung journal of medical sciences2018

Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen.

Satoshi Shinozaki, Hiroyuki Osawa, Hirotsugu Sakamoto, Yoshikazu Hayashi, Yasutoshi Kobayashi, Yoshimasa Miura, Alan Kawarai Lefor, Hironori Yamamoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Role of Vonoprazan inFrontiers in pharmacology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Satoshi ShinozakiShinozaki Medical Clinic, Utsunomiya, Japan; Division of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Hiroyuki OsawaDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan. Electronic address: osawa@jichi.ac.jp.
Hirotsugu SakamotoDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Yoshikazu HayashiDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Yasutoshi KobayashiDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Yoshimasa MiuraDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Alan Kawarai LeforDepartment of Surgery, Jichi Medical University, Shimotsuke, Japan.
Hironori YamamotoDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vonoprazan-based regimens have improved the rate of successful Helicobacter pylori (H. pylori) eradication, but it has not reached 100%. The aim of this study is to clarify significant predictors of successful H. pylori eradication using a vonoprazan-based regimen. In this retrospective cohort study, 174 patients who underwent primary H. pylori eradication therapy were included. All patients underwent esophagogastroduodenoscopy before treatment. The vonoprazan-based regimen includes amoxicillin 750 mg, clarithromycin 200 mg and vonoprazan 20 mg twice daily for one week. Pre-treatment with a proton pump inhibitor (PPI) was defined as continued PPI use for more than four weeks prior to eradication therapy. The rates of successful eradication were 83% (145/174) in intention-to-treat analysis and 85% (145/171) in per-protocol analysis. Predictors of successful eradication among 171 patients were evaluated in per-protocol analysis. In univariate analysis, male gender was a significant positive predictor of successful eradication (odds ratio [OR] 3.813, 95% confidence interval [CI] 1.363-10.663, p = 0.010) and pre-treatment with PPIs was a negative predictor (OR 0.193, 95%CI 0.076-0.485, p < 0.001). In multivariate analysis, male gender remained a positive predictor (OR 3.826, 95%CI 1.317-11.116, p = 0.013), and pre-treatment with PPIs (OR 0.232, 95%CI 0.087-0.615, p = 0.003) remained a negative predictor. In conclusion, pre-treatment with PPIs before eradication therapy decreases the rate of successful eradication. Therefore, it may be desirable to discontinue pre-treatment with PPIs prior to eradication therapy, because of the potential to improve the rate of successful eradication.

Indexed as

AdultAgedAmoxicillinAnti-Bacterial AgentsClarithromycinDrug Therapy, CombinationFemaleHelicobacter InfectionsHumansMaleMiddle AgedProton Pump InhibitorsPyrrolesRetrospective StudiesSulfonamidesTreatment Outcome1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineAmoxicillinAnti-Bacterial AgentsClarithromycinProton Pump InhibitorsPyrrolesSulfonamidesHelicobacter pyloriOutcome measurePotassium-competitive acid blockerProton pump inhibitors

Identifiers

PMID30041763
PMCPMC11915573

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.